eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2026-06-25 23 2 59321 article Sariki Ashok Krishnan 1 Neelamsetti Bala Shankar 1 Posina Naga Venkata Durga Ganga Lakshmi Tulasi 1 Salman Khan, and Shaik Kamarjaha 1 Department of Pharmacology, School of Pharmaceutical Sciences and Technologies, JNTU Kakinada, Andhra Pradesh, India Pancreatic cancer is one of the most fatal cancers because it is often diagnosed only after the disease has progressed to an advanced stage. Early symptoms are often mild or absent, delaying treatment and lowering survival rates. Liquid biopsy has recently emerged as a promising, non-invasive method for early detection by identifying tumor-related materials in blood, such as circulating tumor cells (CTCs) and ctDNA, exosomes and microRNAs. New technologies, including droplet digital PCR, next-generation sequencing, and multi-omics approaches have significantly improved the sensitivity and accuracy of these diagnostic methods. Studies suggest that combining multiple biomarkers with conventional markers such as CA19-9, along with imaging technique may significantly improve early diagnosis. However, challenges such as low tumor shedding in early-stage disease, technical variability, false-positive results, and insufficient large-scale clinical validation still remain. Overall, liquid biopsy holds strong potential for the earlier detection of pancreatic cancer, especially in high-risk individuals; however further well-designed clinical studies are needed before  routine adoption in clinical practice. https://www.biotech-asia.org/vol23no2/recent-advances-in-the-detection-of-pancreatic-cancer-focus-on-liquid-biopsy-and-emerging-biomarkers/ Biomarkers; Liquid biopsy; microRNA; Multi-omics; Pancreatic cancer; Tumor